Opioids: Pharmacology, clinical uses and adverse effects

Opioids: Pharmacology, Clinical Uses and Adverse Effects

Volumn , Issue , 2012, Pages 75-93

  Taylor, Robert ^a   Pergolizzi, Joseph V ^b,c,d   Raffa, Robert B ^e   Muniz, Edmundo ^f  

^a NEMA Research   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^f Tigris Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875933890     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (92)

1. Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993 Jun 15;90(12):5391-3.
2. Scarborough J, Porter R, Teich M. The opium poppy in Hellenistic and Roman medicine Drugs and Narcotics in History: Cambridge University Press; 1995.
3. Huxtable RJ, Schwarz SKW. The Isolation of Morphine-First Principles in Science and Ethics. Molecular Interventions. 2001 October 1, 2001;1(4):189-91.
4. Fine PG, Portenoy RK. A Clinical Guide to Opioid Analgesia. Minneapolis: Healthcare Information Programs; 2004.
5. Thorpe DH. Opiate structure and activity--a guide to understanding the receptor. Anesth Analg. 1984 Feb;63(2):143-51.
6. Goldstein A. Opioid peptides endorphins in pituitary and brain. Science. 1976 Sep 17;193(4258):1081-6.
7. Koneru A, Satyanarayana S, Rizwan S. Endogenous Opioids: Their Physiological Role and Receptors. Global Journal of Pharmacology. 2009;3(3):149-53.
8. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci. 1984; 7:223-55.
9. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004; 73:953-90.
10. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008 Mar; 11(2 Suppl):S133-53.
11. Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ, et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA. 1993 Nov 1; 90(21):9954-8.
12. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009 Jun 5;155(1-3):11-7.
13. Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. British Journal of Anaesthesia. 1998; 81:12-9.
14. Vallejo R, Barkin RL, Wang VC. Pharmacology of Opioids in the Treatment of Chronic Pain Syndromes. Pain Physician. 2011; 14:E343-E60.
15. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002 Jul;24(1):71-90.
16. McNicol E. Opioid Analgesics: Administration Issues, Side-effect management, and equianalgesic conversion. Adv Stud Pharm. 2008;5(1):16-25.
17. Stevens RA, Ghazi SM. Routes of Opioid Analgesic Therapy in the Management of Cancer Pain. Cancer Control. 2000;7(2):132-41.
18. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972 Dec 1;178(64):984-6.
19. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009 Jul;84(7):613-24.
20. Johnson SJ. Opioid Safety in Patients With Renal or Hepatic Dysfunction. Pain Treatment Topics. 2007:1-9.
21. Hudcova J, McNicol E, Quah C, Lau J, Carr DB. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev. 2006(4):CD003348.
22. Colson J, Koyyalagunta D, Falco FJ, Manchikanti L. A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain. Pain Physician. 2011 Mar-Apr;14(2):E85-102.
23. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004 Dec;112(3):372-80.
24. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006; 3:CD006146.
25. Ballanty JC, Shin NS. Efficacy of Opioids for Chronic Pain: A Review of the Evidence. Clin J Pain. 2008;24(6):469-78.
26. Heinke B, Gingl E, Sandkuhler J. Multiple targets of mu-opioid receptor-mediated presynaptic inhibition at primary afferent Adelta-and C-fibers. J Neurosci. 2011 Jan 26;31(4):1313-22.
27. Gibson PG, Ryan NM. Cough pharmacotherapy: current and future status. Expert Opin Pharmacother. 2011 Aug; 12(11):1745-55.
28. Wee B. Chronic cough. Curr Opin Support Palliat Care. 2008 Jun; 2(2):105-9.
29. McNeil-PPC Inc. LOPERAMIDE and LOPERAMIDE-SIMETHICONE Professional Product Information. 2011.
30. Hain RD, Miser A, Devins M, Wallace WH. Strong opioids in pediatric palliative medicine. Paediatr Drugs. 2005;7(1):1-9.
31. Anderson BJ, Palmer GM. Recent developments in the pharmacological management of pain in children. Curr Opin Anaesthesiol. 2006 Jun; 19(3):285-92.
32. Zernikow B, Lindena G. Long-acting morphine for pain control in paediatric oncology. Med Pediatr Oncol. 2001 Apr; 36(4):451-8.
33. Himelstein BP. Palliative care for infants, children, adolescents, and their families. J Palliat Med. 2006 Feb; 9(1):163-81.
34. Drake R, Longworth J, Collins JJ. Opioid rotation in children with cancer. J Palliat Med. 2004 Jun; 7(3):419-22.
35. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008 Jul-Aug;8(4):287-313.
36. Actavis Kadian LLC. KADIAN(r) (morphine sulfate extended-release) Capsules Prescribing Information. 2010.
37. APP Pharmaceuticals. Astramorph (Morphine Sulfate Injection, USP) Preservative Free Prescribing Insert. June 2008.
38. Baxter. Duramorph (morphine sulfate injection) prescribing information. 2011.
39. King Pharmaceuticals. AVINZA (morphine sulfate extended-release capsules) prescribing information. 2011.
40. Purdue Pharmaceuticals. MS Contin (morphine sulfate controlled-release) Tablets Prescribing Information. 2011.
41. Xanodyne Pharmaceuticals. Oramorph SR (morphine sulfate) sustained release tablets prescribing information. 2011.
42. Armstrong S, Cozza K. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality. Psychosomatics. 2003; 44:515-20.
43. Picara. Duragesic (Fentanyl Transdermal System). 2009.
44. Abbott Laboratories. VICODIN ES(r) (hydrocodone bitartrate and acetaminophen tablets, USP). 2011.
45. Abbott Laboratories. Vicoprofen (hydrocodone bitartrate and ibuprofen tablets). 2009.
46. Purdue Pharma. Dilaudid (hydromorphone hydrochloride). 2009.
47. Purdue Pharma. Oxycontin (Oxycodone HCl Controlled Release) Tablets. 2010.
48. Endo Pharmaceuticals. OPANA ER (oxymorphone hydrochloride) Extended-Release tablets, CII. 2010.
49. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010 Sep-Oct;10(5):428-50.
50. Purdue Pharma. Butrans (buprenorphine) Transdermal System, CIII. 2010.
51. Sanofi Aventis. Demerol (meperidine hydrocholoride, USP). 2011.
52. Lynch M. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manage 2005; 10:133-44.
53. Krantz M, Lewkowiez L, Hays H, Woodroffe M, Robertson A, Mehler P. Torsade de pointes associated with very high dose methadone. Ann Intern Med. 2002; 137:501-4.
54. PriCara. ULTRAM ER (tramadol HCI) Extended-Release Tablets. 2009.
55. PriCara. NUCYNTA(r) (tapentadol) Tablets. 2010.
56. Reckitt Benckiser Pharmaceuticals Inc. Suboxone (buprenorphine and naloxone) prescribing information. 2010.
57. Alkermes. Vivitrol (naltrexone for extended release injectable suspension) prescribing information. 2010.
58. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091-7.
59. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003 Jun; 4(5):231-56.
60. Robinson CB, Fritch M, Hullett L, Petersen MA, Sikkema S, Theuninck L, et al. Development of a protocol to prevent opioid-induced constipation in patients with cancer: a research utilization project. Clin J Oncol Nurs. 2000 Mar-Apr; 4(2):79-84.
61. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-71.
62. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001 Nov; 182(5A Suppl):27S-38S.
63. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001 Nov; 182(5A Suppl):19S-26S.
64. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009 May-Jun; 10(4):654-62.
65. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001 Feb;21(2):144-50.
66. Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010 Apr; 25(4):310-5.
67. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998 Jan; 74(1):5-9.
68. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol. 2010 Jan; 35(1):2-6.
69. Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth. 1995 Oct; 42(10):891-903.
70. Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritus. American Journal of Health-System Pharmacy. 2011 August 1, 2011;68(15):1419-25.
71. Dahan A, Aarts L, Smith TW. Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression. Anesthesiology. 2010 Jan; 112(1):226-38.
72. Brunton L, Lazo J, Parker K. Goodman and Gilman's The Pharmacologica Basis of Therapeutics, 11th Edition. New York: McGraw-Hill; 2006.
73. Krantz M, Mehler P. Synthetic opioids and QT prolongation. Arch Intern Med. 2003; 163:1615.
74. Walker P, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: A report of three cases. Pain. 2003; 103:321-4.
75. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011 Mar-Apr;14(2):145-61.
76. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: An emerging iatrogenpression ic syndrome. J Pain Symptom Manage. 2003; 26:769-75.
77. Mao J, Sung B, Ji R, Lim G. Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002; 22:7650-61.
78. Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomedicine & Pharmacotherapy. 2006; 60:310-7.
79. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2008 Mar; 2(1):14-8.
80. Vuong C, Van Uum S, O'Dell L, Lutfy K, Friedman T. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010; 31:98-132.
81. Adams M, Sewing B, Forman J, Meyer E, Cicero T. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther. 1993; 266:323-8.
82. Azizi F, Vagenakis A, Longcope C, Ingbar S, Braverman L. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1973; 22:467-72.
83. Mehmanesh H, Almeida O, Nikolarakis K, Herz A. Hypothalamic LH-RH release after acute and chronic treatment with morphine studied in a combined in vivo/in vitro model. Brain Research. 1988; 451:69-76.
84. Delitala G, Grossman A, Besser G. The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Clin Endocrinol. 1983; 19:437-44.
85. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005; 90:203-6.
86. Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced hypogonadism. BMJ. 2010; 341:c4462.
87. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008; 5:684-92.
88. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008 Mar; 11(2 Suppl):S105-20.
89. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002 Jul; 1(1):13-20.
90. Amato L, Davoli M, Vecchi S, Ali R, Farrell M, Faggiano F, et al. Cochrane systematic reviews in the field of addiction: what's there and what should be. Drug Alcohol Depend. 2011 Jan 15;113(2-3):96-103.
91. Raffa RB, Pergolizzi JV, Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010 Sep 10;70(13):1657-75.
92. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009 Sep; 15(7):556-62.